We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Representative Tumor Sampling Method Lessens Molecular Analyses Bias

By LabMedica International staff writers
Posted on 25 May 2020
Print article
Image: Schematic diagram of how the representative tumor sampling method lessens bias in molecular analyses (Photo courtesy of Francis Crick Institute).
Image: Schematic diagram of how the representative tumor sampling method lessens bias in molecular analyses (Photo courtesy of Francis Crick Institute).
Over the past decade, clinical scientists have demonstrated the inability of an individual biopsy or formalin-fixed paraffin-embedded (FFPE) block to capture the genetic diversity of a solid tumor.

When pathologists extract tumor tissue to identify potential biomarkers for downstream therapy, they deal with issues related to tumor heterogeneity. By analyzing a single sample from a fixed location, they do not always get a representative sample of the cancer, and a tissue biopsy usually only presents less than 0.0005% of the tumor.

Clinical Scientists at the Francis Crick Institute (London, UK) and at Roche Tissue Diagnostics (Tucson, AZ, USA) and their international colleagues have developed a method that they believe could improve clinical tumor molecular profiling by generating accurate tumor mutation burden scores. The team first analyzed data for 1,667 samples across six tumor types from the National Cancer Institute's Cancer Genome Atlas (TCGA). For each sample, they assessed how much of each tumor was sampled.

The system, called Rep-Seq requires at least 1 gram of patient leftover tissue following pathology extraction. The process starts with a pathologist macro-dissecting a sample to remove normal tissue that is at least 5 cm away from the tumor. Tumor and normal tissue are separately incubated and then blended with a specific solution inside a homogenizer. Tumor and immune cells are further separated using fluorescence-activated cell sorting, enriching the representative sample for tumor cells. The group found that tumor sequencing protocols had a high under-sampling bias. Sampling bias was likely also affected by the levels of heterogeneity and purity of tumor cells in the sample.

To determine the effect of spatial bias in single-biopsy sampling, the team pooled extracted DNA from 1,184 multi-region biopsies, taken from 79 primary renal carcinomas (RCCs), to create "cocktail samples." Subjecting the samples to next-generation sequencing (NGS), the team compared mutation calls with previously generated single-biopsy and multi-region biopsy data. They found that the cocktail samples discovered all of the true-set mutations, compared with single biopsies, which only discovered 73%. The team therefore believes that a more representative sample can lead to improved variant detection.

The investigators used tumor masses from leftover material post-surgery, and then applied Rep-Seq on 11 tumors from breast, lung, colorectal, and RCC cancers. Choosing a large clear cell RCC tumor (RS1), the team collected 68 fresh-frozen biopsies from the primary tumor and later homogenized the rest using Rep-Seq. The team performed whole-exome sequencing (WES) on seven biopsies and the Rep-Seq sample, identifying 76 unique mutations. They then compared the Rep-Seq results to the single-biopsy regions and found that the variant allele frequencies (VAFs) from Rep-Seq closely matched the overall tumor VAFs in the 68 biopsies. The group only failed to detect three of the 76 mutations in the Rep-Seq sample.

Samra Turajlic, MBBS, PhD, a Consultant Medical Oncologist and corresponding author of the study, said, “Taking a small sample from a solid cancer, which contains millions or billions of cells, is very problematic, as you deal with the issue of reproducibility. Beyond seeing if there's enough leftover tumor to create a homogenized sample, we wanted to see if the sample will allow you to predict both prognostic and therapeutic markers robustly and accurately.” The study was published on May 5, 2020 in the journal Cell Reports.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.